Applied Genetic Technologies Corp (AGTC) SEC Filing 10-K Annual Report for the fiscal year ending Wednesday, June 30, 2021

Exhibit 99.1

AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021

-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability;

multiple data readouts expected in 2021 and 2022-

-Pre-Clinical programs moving to IND enabling animal studies-

-Company adds experienced industry veterans to board and management team-

-Company to host management update and webcast today at 4:30pm ET-

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 23, 2021— Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced financial results for the fourth quarter and fiscal year ended June 30, 2021.

“During the past 12 months, we made significant progress towards our corporate and clinical goals with the release of meaningful data in our two wholly-owned lead programs and the addition of key industry leaders to our board and executive team as we begin to plan for potential commercialization of these programs,” said Sue Washer, President and CEO of AGTC. “We expect the next 12 months to be a catalyst-rich period as we prepare for data readouts in the XLRP and ACHM programs, additional clinical data from our partnered optogenetics program and the advancement of one or more of our pre-clinical programs towards a potential IND filing.”

Recent Highlights

X-linked Retinitis Pigmentosa (XLRP)

Earlier in the year, the Company reported positive 12-month data from the highest dose groups in the Company’s ongoing XLRP Phase 1/2 clinical trial, including 12-month data from Groups 5 and 6 reflecting a 50% response rate among patients who meet the inclusion criteria for the Skyline and Vista trials and 24-month data from the two of three Group 4 patients providing preliminary evidence of response durability. The third patient was not a responder at month 12 and the Company is awaiting data on the remaining four Group 4 patients. Taken together, these data add to the body of evidence suggesting that durable improvements in visual sensitivity and visual acuity may be achieved in patients receiving AGTC’s XLRP product candidate while continuing to demonstrate a favorable safety profile.

The Company is currently conducting the Skyline and Vista Phase 2/3 clinical trials to support a potential filing of a biologics license application, or BLA.    Due to several challenges related to the COVID pandemic, including a greater than 50% patient screening cancellation rate in July and August, AGTC is amending its guidance on the three-month Skyline interim data release to the first half of 2022, but maintaining the six-month Vista interim data release for 4Q 2022.

In July 2021, The United States Adopted Name (USAN) Council notified the Company that it has formally assigned the USAN name laruparetigene zosaparvovec for its XLRP product candidate. Subject to positive data readouts in 2022, the Company intends to evaluate potential commercial or trade names for this product candidate.